Job title: Director - Technology Development & Synthetic Biochemistry Leader
Doug Fuerst is currently Head of Synthetic Biochemistry at GlaxoSmithKline leading enzyme engineering efforts for biocatalysis. Doug obtained his PhD in natural product total synthesis from Yale University, followed by postdoctoral research at Harvard University studying asymmetric catalysis. Doug joined GSK in the Chemical Development department working on the discovery and development of large scale chemical processes with an emphasis on biocatalysis.
Accelerating The Adoption of Biocatalysis In the Pharmaceutical Industry 10:00 am
• Explore strategies for early adoption of enzymes in pharmaceutical routes • Analyze modern techniques to identify novel enzyme starting points from existing genetic diversity and computational design • Evaluate rapid directed evolution approaches to optimize enzymes for early phase pharmaceutical applicationsRead more
day: Day Two